Purpose: Investigating some side effects of adjuvant capecitabine and oxaliplatin for gastric cancer after gastrectomy. Patients and Meqrods: Descriptive study on 45 patients have treated adjuvant chemotherapy by capecitabine and oxaliplatin in the Hanoi Medical University hospital and K hospital from January, 2011 to September, 2013. Results: Age 40
Male/female: 1.25/1. Time starting is 30.5 + or - 7.8 days
97.8 percent of patients had completed 8 cycles
100 percent of patients had used over 85 percent of chemotherapeutic standard dose. Neutropenia: 31.9 percent (grade 3.4: 2.2 percent)
hematopenia: 41.6 percent (without seriously hematopenia)
thrompocytopenia: 28.3 percent (without grade 3.4)
increase AST/AL T: 47.6 percent (grade 3.4: 0.5 percent). Hyperbillirubinemia: 20.2 percent (grade 3.4: 4.8 percent)
increase Creatinin: 3.4 percent (without grade 2-4). Peripheral neuropathy: 51 percent (without grade 3.4)
Hand-foot syndrome: 46.7 percent (without grade 3.4)
Decreased appetite: 40 percent (without grade 3.4)
Nausea: 31.2 percent (without grade 3.4)
Vomiting: 27.7 percent (without grade 3.4)
Diarrhoea: 16.8 percent (without grade 3.4)
Constipation: 4.5 percent (without grade 2-4)
non loss hair. Conclusion: Xelox regimen is safely, has less seriously toxicity in adjuvant chemotherapy for gastric cancer patients.